Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Knop

Showing results (11-20 of 508) with videos related to

Pageof 51
Sort By:
Applied Optics|November 2, 2010
Passive focus sensorK Engelhardt, K Knop
The Journal of Clinical Endocrinology and Metabolism|October 21, 2019
Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid PhysiologyAndreas Brønden, Filip K Knop
Nature Reviews. Endocrinology|August 29, 2012
Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?Mikkel Christensen, Filip K Knop
Diabetes Care|July 25, 2013
Mechanism of metabolic advantages after bariatric surgery: it's all gastrointestinal factors versus it's all food restrictionFilip K Knop, Roy Taylor
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 10, 2008
Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitusTina Vilsbøll, Filip K Knop
Current Diabetes Reports|April 29, 2010
Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?Mikkel Christensen, Filip K Knop
Nature Reviews. Endocrinology|May 6, 2017
Therapy: Liraglutide - preventing or postponing T2DM diagnosis?Tina Vilsbøll, Filip K Knop
Diabetes|August 28, 2012
Comment on: Gögebakan et al. Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11β-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids. Diabetes 2012;61:292-300Filip K Knop, Mikkel Christensen
Diabetes Research and Clinical Practice|June 27, 2018
Extrapancreatic glucagon: Present statusAsger Lund, Filip K Knop
Current Medical Research and Opinion|April 3, 2012
Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylureaAsger Lund, Filip K Knop
Pageof 51

Showing results (11-20 of 508) with videos related to

Sort By:
Pageof 51
Applied Optics|November 2, 2010
Passive focus sensorK Engelhardt, K Knop
The Journal of Clinical Endocrinology and Metabolism|October 21, 2019
Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid PhysiologyAndreas Brønden, Filip K Knop
Nature Reviews. Endocrinology|August 29, 2012
Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?Mikkel Christensen, Filip K Knop
Diabetes Care|July 25, 2013
Mechanism of metabolic advantages after bariatric surgery: it's all gastrointestinal factors versus it's all food restrictionFilip K Knop, Roy Taylor
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 10, 2008
Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitusTina Vilsbøll, Filip K Knop
Current Diabetes Reports|April 29, 2010
Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?Mikkel Christensen, Filip K Knop
Nature Reviews. Endocrinology|May 6, 2017
Therapy: Liraglutide - preventing or postponing T2DM diagnosis?Tina Vilsbøll, Filip K Knop
Diabetes|August 28, 2012
Comment on: Gögebakan et al. Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11β-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids. Diabetes 2012;61:292-300Filip K Knop, Mikkel Christensen
Diabetes Research and Clinical Practice|June 27, 2018
Extrapancreatic glucagon: Present statusAsger Lund, Filip K Knop
Current Medical Research and Opinion|April 3, 2012
Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylureaAsger Lund, Filip K Knop
Pageof 51